Dual inhibition of EGFR and c-Src by cetuximab and dasatinib combined with FOLFOX chemotherapy in metastatic colorectal cancer (CA180048)
Phase of Trial: Phase I/II
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Cetuximab (Primary) ; Dasatinib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Mar 2017 Status changed from active, no longer recruiting to completed.
- 09 Mar 2017 Results (n=77) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 07 Jan 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2018 as reported by ClinicalTrials.gov record.